Every material Form 8-K SELLAS Life Sciences Group, Inc. has filed with the SEC since June 25, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
SELLAS reported a second-quarter 2026 net loss of $9.6 million, or $0.05 per share, up from $6.6 million, or $0.07 per share, a year earlier, as research and development and general and administrative expenses rose. Cash and cash equivalents were $138.3 million at June 30, 2026, up from $71.8 million at December 31, 2025, and the company said the final analysis of its Phase 3 REGAL trial will follow the 80th event.
Q2 2026 net loss $9.6 million ($0.05 per share) vs. $6.6 million ($0.07 per share) in Q2 2025
R&D expenses $6.3 million vs. $3.9 million; G&A expenses $4.4 million vs. $3.0 million
Cash and cash equivalents $138.3 million at June 30, 2026, vs. $71.8 million at December 31, 2025
Phase 3 REGAL final analysis to follow the pre-specified 80th event; SLS009 Phase 2 topline data expected in Q4 2026
An arbitrator dismissed SELLAS's claims against licensee 3D Medicines on July 24, 2026, and allocated about $1.0 million of 3D Medicines' legal fees and costs to be paid by SELLAS. The filing also gives unaudited cash and cash equivalents of $138.3 million as of June 30, 2026, which may differ materially from the figures in the company's final financial statements. The dismissal removes SELLAS's claims over $13.0 million in disputed milestone payments, while 3D Medicines says it will continue developing galinpepimut-S in Greater China.
On July 24, 2026, the sole arbitrator in the HKIAC arbitration dismissed SELLAS's claims against 3D Medicines.
SELLAS must pay approximately $1.0 million of 3D Medicines' legal fees and costs, as allocated by the arbitrator.
Unaudited cash and cash equivalents were $138.3 million as of June 30, 2026, subject to financial closing procedures.
$191.5 million in potential future milestone payments remained under the license as of March 31, 2026, including the $13.0 million in dispute.
SELLAS Life Sciences Group amended its CEO's employment agreement and entered amended severance agreements with its CFO and Chief Development Officer, all dated June 24, 2026. The changes set out payment terms if these executives are terminated, including enhanced change-of-control benefits, and the filing does not report any change in executive roles.
CEO Dr. Angelos Stergiou's change-in-control severance payments will be paid as a lump sum under an amendment to his employment agreement.
CFO John Burns and Dr. Dragan Cicic received amended agreements; within one month before or one year after a change of control, each is entitled to a lump sum of 15 months' base salary plus target bonus.
Outside a change-of-control period, severance is nine months of base salary, pro rata target bonus paid over nine months, and up to nine months of COBRA reimbursement.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every SELLAS Life Sciences Group, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →